SCHEDULE: Ameriprise Financial Discloses Palisade Bio Stake

Ameriprise Financial, Inc. and its subsidiary Columbia Management Investment Advisers, LLC have reported beneficial ownership of 5.3% of Palisade Bio, Inc.'s common stock as of March 31, 2026.

Summary

• Ameriprise Financial, Inc. (AFI) and its subsidiary Columbia Management Investment Advisers, LLC (CMIA) have filed a Schedule 13G.
• This filing indicates that CMIA beneficially owns 8,711,385 shares of Palisade Bio, Inc. common stock.
• This ownership represents 5.3% of the class of securities.
• AFI, as the parent company of CMIA, may be deemed to beneficially own these shares.
• Both AFI and CMIA disclaim beneficial ownership of any shares reported on this Schedule, suggesting these holdings are managed on behalf of other clients.
• The filing is dated May 15, 2026, and reflects the ownership as of March 31, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It's a standard disclosure of institutional ownership without any commentary on the company's performance or future prospects.

Positives

• Significant institutional ownership by a major financial services firm (Ameriprise Financial) can indicate confidence in the company's long-term prospects.
• The filing clearly delineates ownership percentages, providing transparency to the market.

Negatives

• The disclaimer of beneficial ownership by both AFI and CMIA suggests these shares are held in a fiduciary capacity for clients, not as a strategic investment by Ameriprise itself, which might limit the 'vote of confidence' interpretation.

Risks

• The filing does not contain any specific risks related to Palisade Bio, Inc. or the ownership stake.

Future Outlook

The filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Palisade Bio, Inc.'s future performance.

Management Comments

• "Each of AFI and CMIA disclaims beneficial ownership of any shares reported on this Schedule."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures for institutional investors crossing certain ownership thresholds. This filing indicates a notable position held by Ameriprise Financial, a large asset manager, in Palisade Bio, Inc., a biotechnology company.

Stakeholder Impact

• Shareholders: Increased transparency regarding institutional ownership, which can influence market perception.
• Ameriprise Financial Clients: Confirmation that their assets are managed by a large, reputable firm, though the disclaimer suggests these are client holdings, not direct corporate investments.

Next Steps

• No specific next steps are outlined in this filing.

Key Dates

Keywords

Palisade Bio, Ameriprise Financial, Columbia Management, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing